Providers are up to three times more likely to trust the opinion of humans over AI, even when the algorithm is proven to detect more cancerous lesions than radiologists.
Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at the American College of Cardiology (ACC) 2025 meeting in late March, showed positive results for the Evolut transcatheter aortic valve replacement (TAVR) system vs. surgical aortic valve replacement (SAVR).
Two separate studies examined the controversial topic of prescribing statins to high-risk elderly patients who do not already have high cholesterol or cardiovascular disease.
Researchers focused on 22 pairs of identical twins for 8 weeks, asking one twin to follow a healthy vegan diet and the other to follow a healthy omnivorous diet.
Avidity Biosciences, a San Diego-based biopharmaceutical company, is expanding its ongoing collaboration with Bristol Myers Squibb to identify new cardiovascular therapies.